Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2015-02-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C–2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE: Parliamentary submission
DATE: 2014-10-28
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

October 28, 2014

Canadian Medical Association

CMA Policybase - Canadian Medical Association
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11519

POLICY TYPE  Parliamentary submission
DATE  2015-05-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-17 An Act to amend the Food and Drugs Act
https://policybase.cma.ca/link/policy11196

POLICY TYPE
Parliamentary submission

DATE
2014-06-11

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

POLICY TYPE  Parliamentary submission
DATE  2017-08-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE  Parliamentary submission
DATE  2018-04-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE  Policy endorsement
DATE  2017-05-26
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase

https://policybase.cma.ca/link/policy11129

POLICY TYPE
Parliamentary submission

DATE
2014-05-15

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy10045

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2010-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY

Cannabis for Medical Purposes

Cannabis for Medical Purposes

The Canadian Medical Association (CMA), has always recognized the unique requirements of those individuals suffering from a terminal illness or chronic disease for which conventional therapies have not been effective and for whom cannabis is an option. The CMA notes with concern that a number of provinces, territories and municipalities have been considering the decriminalization of cannabis. The CMA remains committed to ensuring that any such action takes into account the health needs of all Canadians, including those who suffer from a terminal illness or chronic disease.

The CMA makes the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis. The CMA recommends that the federal government support scientific research to assess the efficacy of cannabis for the treatment of a variety of conditions, including cancer, multiple sclerosis, and pain.

2. Increase support for the implementation of regulations governing the medical use of cannabis. The CMA recommends that the federal government work closely with the provinces and territories to ensure that any regulations governing the medical use of cannabis are evidence-based and reflect the best available scientific knowledge.

3. Increase support for the implementation of regulations governing the medical use of cannabis. The CMA recommends that the federal government work closely with the provinces and territories to ensure that any regulations governing the medical use of cannabis are evidence-based and reflect the best available scientific knowledge.

The CMA encourages its members to support these recommendations and to work with their local and provincial/territorial medical associations to ensure that the medical use of cannabis is regulated in a manner that is consistent with the best available scientific knowledge.
CMA Presentation to the Senate Standing Committee on Social Affairs, Science and Technology – Prescription Drugs: Clinical Trials and Approval
https://policybase.cma.ca/link/policy10437

POLICY TYPE  Parliamentary submission
DATE  2012-05-09
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Response: Health Canada’s Medical Marijuana Regulatory Proposal
https://policybase.cma.ca/link/policy10702

POLICY TYPE
Parliamentary submission

DATE
2013-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

A healthy population needs a coherent medical profession that can take on the role of a primary care provider. This role is needed to ensure the well-being of the population and to prevent and treat illnesses.
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE: Response to consultation
DATE: 2017-06-28
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE: Parliamentary submission
DATE: 2017-04-07
TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
CMA’s recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

Submission to the Senate Standing Committee on Social Affairs, Science and Technology

April 7, 2017
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

POLICY TYPE          Parliamentary submission
DATE                2018-02-15
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs
                      Health care and patient safety

Documents
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)

https://policybase.cma.ca/link/policy11599

POLICY TYPE  Response to consultation
DATE  2015-06-08
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA's Submission to the House of Commons Standing Committee on Health:
Drug Shortages
https://policybase.cma.ca/link/policy10382

POLICY TYPE
Parliamentary submission

DATE
2012-03-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety
https://policybase.cma.ca/link/policy11125

POLICY TYPE  Parliamentary submission
DATE  2014-03-26
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology – Prescription Pharmaceuticals in Canada: The Post-Approval Monitoring of Prescription Pharmaceuticals

https://policybase.cma.ca/link/policy10631

POLICY TYPE  Parliamentary submission
DATE  2012-10-24
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents